► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs

Valeant’s stock has plummeted as critics allege price gouging in the pharma group’s portfolio of generic drugs. Lex’s Robert Armstrong and Jonathan Eley discuss whether the sell-off is overdone.


For more video content from the Financial Times, visit http://www.FT.com/video


Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes